{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:01:39Z","timestamp":1775239299726,"version":"3.50.1"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Natural Science Foundation of Hunan province Youth Fund","award":["2024JJ6685"],"award-info":[{"award-number":["2024JJ6685"]}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ20096"],"award-info":[{"award-number":["2022JJ20096"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Postdoctoral International Exchange Program of China Postdoc Council","award":["YJ20210203"],"award-info":[{"award-number":["YJ20210203"]}]},{"DOI":"10.13039\/501100001809","name":"National Youth Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82200863"],"award-info":[{"award-number":["82200863"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273121"],"award-info":[{"award-number":["82273121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Programmed death-ligand 1 (PD-L1) positivity is associated with a favorable response to immune checkpoint blockade (ICB) in urothelial bladder cancer (BLCA). However, the efficacy of ICB in BLCA exhibits considerable heterogeneity, leading to the need for complementary predictive biomarkers. Recent studies suggest that a high degree of plasma cell infiltration is correlated with improved benefit from ICB, but a specific plasma cell marker in BLCA has not been identified. The aim of this study was to evaluate tumor necrosis factor receptor superfamily member 17 (TNFRSF17) as a plasma cell-specific marker in BLCA and test its utility, combined with PD-L1, for patient stratification receiving ICB therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Transcriptomic and clinical data from publicly available cohorts were analyzed. Plasma cell-associated markers were identified based on expression specificity and correlation analyses. The clinical relevance of TNFRSF17, alone and in combination with CD274, was evaluated by comparisons of survival and the response rate. Associations with immunotherapy-related features were examined using established surrogate measures, including the immunophenoscore.\n                      <jats:italic>In silico<\/jats:italic>\n                      deconvolution analyses were performed to characterize the immunogenic tumor microenvironment by comparing distinct immune infiltration patterns and differential gene expression pathways between the subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Plasma cell infiltration correlated with favorable survival in BLCA patients. Higher expression of TNFRSF17, a plasma cell-specific marker (R\u2009=\u20090.73\u2009\u00b1\u20090.15; z score\u2009=\u20091.88\u2009\u00b1\u20090.41), correlated with increased immunophenoscores, more favorable overall survival outcomes (HR\u2009=\u20090.59) and increased responsiveness to ICB therapy. Tumors with concurrent high TNFRSF17 and CD274 expression exhibited the most favorable survival outcomes (HR\u2009=\u20090.38) and demonstrated an immune-inflamed transcriptional profile, including enrichment of antigen presentation and immune signaling pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TNFRSF17 serves as a potential marker to characterize an immune-distinct and prognostically favorable subgroup within CD274High tumors, and to refine stratification for ICB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0346131","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:24:58Z","timestamp":1775237098000},"page":"e0346131","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer"],"prefix":"10.1371","volume":"21","author":[{"given":"Jiawen","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-0083","authenticated-orcid":true,"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"3","key":"pone.0346131.ref001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1215","article-title":"Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"7","author":"BA Maiorano","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10122","key":"pone.0346131.ref002","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"T Powles","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"pone.0346131.ref003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024","article-title":"Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial","volume":"80","author":"MS van der Heijden","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"pone.0346131.ref004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13059-021-02325-y","article-title":"Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer","volume":"22","author":"T Iyyanki","year":"2021","journal-title":"Genome Biol"},{"issue":"17","key":"pone.0346131.ref005","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1200\/JCO.22.02144","article-title":"Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade","volume":"41","author":"M Sarfaty","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7693","key":"pone.0346131.ref006","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"S Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"9","key":"pone.0346131.ref007","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians","volume":"31","author":"V Subbiah","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"pone.0346131.ref008","doi-asserted-by":"crossref","first-page":"100744","DOI":"10.1016\/j.xcrm.2022.100744","article-title":"Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity","volume":"3","author":"B Mirlekar","year":"2022","journal-title":"Cell Rep Med"},{"issue":"7","key":"pone.0346131.ref009","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1066896916653673","article-title":"CD138 Expression Is Observed in the Urothelial Epithelium and in Various Urothelial Carcinomas, and Cannot Be Evidence for Plasmacytoid Urothelial Carcinoma","volume":"24","author":"K Goto","year":"2016","journal-title":"Int J Surg Pathol"},{"key":"pone.0346131.ref010","first-page":"100779","article-title":"Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications","volume":"37","author":"K Weiss","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"pone.0346131.ref011","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","article-title":"Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer","volume":"22","author":"DR Kroeger","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"pone.0346131.ref012","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.17397","article-title":"B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy","volume":"193","author":"L Bernabei","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"pone.0346131.ref013","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00384-011-1364-8","article-title":"The haplotypes of TNFRSF17 polymorphisms are associated with colon cancer in a Korean population","volume":"27","author":"S-C Chae","year":"2012","journal-title":"Int J Colorectal Dis"},{"key":"pone.0346131.ref014","doi-asserted-by":"crossref","first-page":"941208","DOI":"10.3389\/fonc.2022.941208","article-title":"CD8+ T cell-associated genes MS4A1 and TNFRSF17 are prognostic markers and inhibit the progression of colon cancer","volume":"12","author":"Y Song","year":"2022","journal-title":"Front Oncol"},{"key":"pone.0346131.ref015","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"T Li","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"pone.0346131.ref016","first-page":"100625","article-title":"Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors","volume":"5","author":"B Gy\u0151rffy","year":"2024","journal-title":"Innovation (Camb)"},{"issue":"9","key":"pone.0346131.ref017","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41401-023-01079-6","article-title":"Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors","volume":"44","author":"SA Kov\u00e1cs","year":"2023","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"pone.0346131.ref018","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41392-025-02438-x","article-title":"Single-cell RNA-seq reveals cell type-specific molecular and genetic associations with primary open-angle glaucoma","volume":"10","author":"H Tian","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"pone.0346131.ref019","doi-asserted-by":"crossref","first-page":"100444","DOI":"10.1016\/j.xgen.2023.100444","article-title":"Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities","volume":"4","author":"Y Liu","year":"2024","journal-title":"Cell Genom"},{"issue":"4","key":"pone.0346131.ref020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","article-title":"Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy","volume":"43","author":"SL Wang","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"pone.0346131.ref021","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"B Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"pone.0346131.ref022","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltae003","article-title":"Tumour-reactive plasma cells in antitumour immunity: current insights and future prospects","volume":"4","author":"P Chen","year":"2024","journal-title":"Immunother Adv"},{"issue":"24","key":"pone.0346131.ref023","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","article-title":"Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer","volume":"24","author":"MCA Wouters","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:25:02Z","timestamp":1775237102000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346131"}},"subtitle":[],"editor":[{"given":"Alexis G. Murillo","family":"Carrasco","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0346131","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}